MarketsFeatured
8.4
Lilly launches Foundayo oral GLP-1 competing with Novo Nordisk's Wegovy
Eli Lilly has introduced Foundayo, a once-daily oral GLP-1 receptor agonist for weight loss, entering the competitive pharmaceutical market dominated by Novo Nordisk's Wegovy injection. The pill formulation addresses patient preference for oral administration over injections, potentially reshaping the weight-loss drug market. Market implications include competitive pricing pressure and expanded addressable patient population.